Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?

Danesi, R; Del Re, M; Ciccolini, J; Schellens, J H M; Schwab, M; van Schaik, R H N; van Kuilenburg, A B P

Danesi, R; Del Re, M; Ciccolini, J; Schellens, J H M; Schwab, M; van Schaik, R H N; van Kuilenburg, A B P.

Afiliação

Danesi R; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Del Re M; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Ciccolini J; Clinical Pharmacokinetics, La Timone University Hospital, Marseille, and GPCO-Unicancer, Paris, France.
Schellens JHM; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Schwab M; Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and Department of Clinical Pharmacology, University Hospital, Tuebingen, Germany.
van Schaik RHN; IFCC Reference center - Pharmacogenetics, Department of Clinical Chemistry, Erasmus University, Rotterdam.
van Kuilenburg ABP; Department of Clinical Chemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Ann Oncol ; 28(1): 183, 2017 01 01.

Article em En | MEDLINE | ID: mdl-27687313

Assuntos

Di-Hidrouracila Desidrogenase (NADP); Fluoruracila; Hipersensibilidade a Drogas; Humanos; Pirimidinas

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Di-Hidrouracila Desidrogenase (NADP) / Fluoruracila Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google